Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 235895, 5 pages
http://dx.doi.org/10.1155/2015/235895
Clinical Study

Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia

1Department of Urology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China
2Department of Urology, Guizhou Provincial People’s Hospital, Guizhou 550002, China
3Guizhou Provincial Key Laboratory of Computational Nano-Material Science, Guizhou Normal College, Guiyang 550018, China
4Department of Pathology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China
5Department of Urology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, China

Received 21 July 2014; Revised 10 August 2014; Accepted 17 August 2014

Academic Editor: Zhenyu Jia

Copyright © 2015 Li Ruan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Tubaro, S. Mariani, C. de Nunzio et al., “Bladder weight and detrusor thickness as parameters of progression of benign prostatic hyperplasia,” Current Opinion in Urology, vol. 20, no. 1, pp. 37–42, 2010. View at Google Scholar
  2. G. Gandaglia, A. Briganti, P. Gontero et al., “The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH),” BJU International, vol. 112, no. 4, pp. 432–441, 2013. View at Google Scholar
  3. H. Kwon, H. C. Kang, and J. H. Lee, “Relationship between predictors of the risk of clinical benign and metabolic syndrome in men with moderate to severe lower urinary tract symptoms,” Urology, vol. 81, no. 6, pp. 1325–1329, 2013. View at Google Scholar
  4. J. Moreno Sierra, C. Fernandez Pérez, S. Cano Escudero et al., “Progression of null or mild lower urinary tract symptoms indicative of benign prostatic hyperplasia after 2 years of follow-up in non-treated men aged 40 years or older,” Urology, vol. 77, no. 3, pp. 693–698, 2011. View at Google Scholar
  5. A. D. Lamb, M. Qadan, S. Roberts et al., “CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia,” BJU International, vol. 108, no. 2, part 2, pp. E43–E50, 2011. View at Google Scholar
  6. G. W. Cannon and R. H. Getzenberg, “Biomarkers for benign prostatic hyperplasia progression,” Current Urology Reports, vol. 9, no. 4, pp. 279–283, 2008. View at Google Scholar
  7. A. Descazeaud, N. Weinbreck, G. Robert et al., “Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation,” BJU International, vol. 108, no. 2, part 2, pp. E23–E28, 2011. View at Publisher · View at Google Scholar
  8. T. P. Pejcic, C. D. Tulic, N. V. Lalic et al., “Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?” The Canadian Journal of Urology, vol. 20, no. 2, pp. 6707–6713, 2013. View at Google Scholar
  9. G. Espinosa, R. Esposito, A. Kazzazi et al., “Vitamin D and benign prostatic hyperplasia-areview,” The Canadian Journal of Urology, vol. 20, no. 4, pp. 6820–6825, 2013. View at Google Scholar
  10. J. M. Valdivielso and E. Fernandez, “Vitamin D receptor polymorphisms and diseases,” Clinica Chimica Acta, vol. 371, no. 1-2, pp. 1–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Zajícková, A. Krepelová, I. Zofková et al., “A single nucleotide polymorphism under the reverse primer binding site may lead to BsmI mis-genotyping in the vitamin D receptor gene,” Journal of Bone and Mineral Research, vol. 18, no. 10, pp. 1754–1757, 2003. View at Google Scholar
  12. J. J. Oh, S. S. Byun, S. E. Lee et al., “Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population,” Gene, vol. 533, no. 1, pp. 86–93, 2014. View at Publisher · View at Google Scholar
  13. P. K. Manchanda, R. Konwar, V. L. Nayak, V. Singh, and H. K. Bid, “Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-I, Taq-I and Bsm-I) with susceptibility of benign prostatic hyperplasia in a North Indian population,” Asian Pacific Journal of Cancer Prevention, vol. 11, no. 4, pp. 1005–1008, 2010. View at Google Scholar
  14. A. A. El Ezzi, W. R. Zaidan, M. A. El-Saidi, N. Al-Ahmadieh, J. B. Mortenson, and R. H. Kuddus, “Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1255–1262, 2014. View at Google Scholar
  15. S. Wu and J. Sun, “Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection,” Discovery Medicine, vol. 11, no. 59, pp. 325–335, 2011. View at Google Scholar
  16. C. Wang, H. Zhao, L. Xiao et al., “Association between vitamin D receptor gene polymorphisms and severe chronic periodontitis in a Chinese population,” Journal of Periodontology, vol. 80, no. 4, pp. 603–608, 2009. View at Google Scholar
  17. L. Ruan, W.-D. Zhong, Z.-M. Li, and X. Hua, “[Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis,” National journal of andrology, vol. 17, no. 10, pp. 880–883, 2011 (Chinese). View at Google Scholar · View at Scopus
  18. C.-W. Fwu, P. W. Eggers, S. A. Kaplan, Z. Kirkali, J. Y. Lee, and J. W. Kusek, “Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia,” The Journal of Urology, vol. 190, no. 1, pp. 187–193, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Dutkiewicz, A. Witeska, and K. Stepien, “Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH),” International Urology and Nephrology, vol. 27, no. 6, pp. 763–768, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Tsujii, “Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study,” International Journal of Urology, vol. 7, no. 6, pp. 199–205, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Huang, J. Qi, Y. Yu et al., “Transitional zone index and intravesical prostatic protrusion in benign prostatic hyperplasia patients: Correlations according to treatment received and other clinical data,” Korean Journal of Urology, vol. 53, no. 4, pp. 253–257, 2012. View at Publisher · View at Google Scholar · View at Scopus